Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner

Abstract

p53 is present at low levels in unstressed cells. Numerous cellular insults, including DNA damage and microtubule disruption, elevate p53 protein levels. Phosphorylation of p53 is proposed to be important for p53 stabilization and activation after genotoxic stress; however, p53 phosphorylation after microtubule disruption has not been analysed. The goal of the current study was to determine if p53 phosphorylation increases after microtubule disruption, and if so, to identify specific p53 residues necessary for microtubule inhibitor-induced phosphorylation. Two dimensional gel analyses demonstrated that the number of p53 phospho-forms in cells increased after treatment with microtubule inhibitors (MTIs) and that the pattern of p53 phosphorylation was distinct from that observed after DNA damage. p53 phosphorylation also varied in a MTI-dependent manner, as Taxol and Vincristine induced more p53 phospho-forms than nocodazole. Further, MTI treatment increased phosphorylation of p53 on serine-15 in epithelial tumor cells. In contrast, serine-15 phosphorylation of p53 did not increase in MTI-treated primary cultures of human fibroblasts. Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53. Taken together, the results of this study demonstrate that distinct p53 phospho-forms are induced by MTI treatment as compared to DNA damage and that p53 phosphorylation is mediated in a MTI- and cell-specific manner.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Abraham J, Kelly J, Thibault P and Benchimol S. . 2000 J. Mol. Biol. 295: 853–864.

  • Ashcroft M, Kubbutat MHG and Vousden KH. . 1999 Mol. Cell. Biol. 19: 1751–1758.

  • Ashcroft M, Taya Y and Vousden KH. . 2000 Mol. Cell. Biol. 20: 3224–3233.

  • Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y. . 1998 Science 281: 1674–1677.

  • Baudier J, Delphin C, Grunwald D, Khochbin S and Lawrence JJ. . 1992 Proc. Natl. Acad. Sci. USA 89: 11627–11631.

  • Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ and Herrlich P. . 1999 Oncogene 18: 1723–1732.

  • Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E and Fornace Jr AJ. . 1999 EMBO J. 18: 6845–6854.

  • Canman CE and Lim DS. . 1998 Oncogene 17: 3301–3308.

  • Canman CE, Lim DS, Cimprich KA, Taya K, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD. . 1998 Science 281: 1677–1679.

  • Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD. . 1999 Proc. Natl. Acad. Sci. USA 96: 13777–13782.

  • Chehab NH, Malikzay A, Appel M and Halazonetis TD. . 2000 Genes Dev. 14: 278–288.

  • Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A and Hupp TR. . 1999 Biochem. J. 342: 133–141.

  • Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ. . 1995 Science 267: 1353–1356.

  • Cuddihy AR, Wong AH, Tam NW, Li S and Koromilas AE. . 1999 Oncogene 18: 2690–2702.

  • Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G and Wahl GM. . 1997 Cancer Res. 57: 1013–1019.

  • Dumaz N, Milne DM and Meek DW. . 1999 FEBS Lett. 463: 312–316.

  • Flatt PM, Tang LJ, Scatena CD, Szak ST and Pietenpol JA. . 2000 Mol. Cell. Biol. 20: 4210–4223.

  • Furnari B, Rhind N and Russell P. . 1997 Science 277: 1495–1497.

  • Gao CF, Nakajima T, Taya Y and Tsuchida N. . 1999 Biochem. Biophys. Res. Commun. 264: 860–864.

  • Hall SR, Campbell LE and Meek DW. . 1996 Nucleic Acids Res. 24: 1119–1126.

  • Hall-Jackson CA, Cross DA, Morrice N and Smythe C. . 1999 Oncogene 18: 6707–6713.

  • Haupt Y, Maya R, Kazaz A and Oren M. . 1997 Nature 387: 296–299.

  • Hecker D, Page G, Lohrum M, Weiland S and Scheidtmann KH. . 1996 Oncogene 12: 953–961.

  • Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW. . 2000 Science 287: 1824–1827.

  • Hupp TR, Meek DW, Midgley CA and Lane DP. . 1992 Cell 71: 875–886.

  • Khan SH and Wahl GM. . 1998 Cancer Res. 58: 396–401.

  • Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y and Shkedy D. . 1999 Proc. Natl. Acad. Sci. USA 96: 14973–14977.

  • Knippschild U, Milne DM, Campbell LE, DeMaggio AJ, Christenson E, Hoekstra MF and Meek DW. . 1997 Oncogene 15: 1727–1736.

  • Kubbutat MHG, Jones SN and Vousden KH. . 1997 Nature 387: 299–303.

  • Lanni JS and Jacks T. . 1998 Mol. Cell. Biol. 18: 1055–1064.

  • Lavin MF and Shiloh Y. . 1996 Curr. Opin. Immunol. 8: 459–464.

  • Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E and Anderson CW. . 1992 Mol. Cell. Biol. 12: 5041–5049.

  • Li L, Ljungman M and Dixon JE. . 2000 J. Biol. Chem. 275: 2410–2414.

  • Matsuoka S, Huang M and Elledge SJ. . 1998 Science 282: 1893–1897.

  • Mayo LD, Turchi JJ and Berberich SJ. . 1997 Cancer Res. 57: 5013–5016.

  • Milne DM, Palmer RH, Campbell DG and Meek DW. . 1992 Oncogene 7: 1361–1369.

  • Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD and Gazdar AF. . 1992 Oncogene 7: 171–180.

  • Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL. . 1999 Genes Dev. 13: 2490–2501.

  • Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW and Appella E. . 2000 J. Biol. Chem. 275: 9278–9283.

  • Sanchez Y, Wong S, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ. . 1997 Science 277: 1497–1501.

  • Sherr CJ and Weber JD. . 2000 Curr. Opin. Genet. Dev. 10: 94–99.

  • Shieh SY, Ikeda M, Taya Y and Prives C. . 1997 Cell 91: 325–334.

  • Shieh SY, Ahn J, Tamai K, Taya Y and Prives C. . 2000 Genes Dev. 14: 289–300.

  • Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB. . 1997 Genes Dev. 11: 3471–3481.

  • Stewart ZA, Leach SD and Pietenpol JA. . 1999a Mol. Cell Biol. 19: 205–215.

  • Stewart ZA, Mays D and Pietenpol JA. . 1999b Cancer Res. 59: 3831–3837.

  • Szak ST and Pietenpol JA. . 1999 J. Biol. Chem. 274: 3904–3909.

  • Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT. . 1999 Genes Dev. 13: 152–157.

  • Wang Y and Prives C. . 1995 Nature 376: 88–91.

  • Waterman MJF, Stavridi ES, Waterman JLF and Halazonetis TD. . 1998 Nature Genet. 19: 175–178.

  • Wu L and Levine AJ. . 1997 Mol. Med. 3: 441–451.

Download references

Acknowledgements

The authors thank Drs Karen Vousden (NCI) and Peter Herrlich (Institut für Genetik) for the p53 phosphorylation-site mutants. This work was supported by Susan G. Komen Breast Cancer Foundation Grant 99-3038 (ZA Stewart), National Institutes of Health Institutional Training Grant GM07347 (ZA Stewart), National Institutes of Health Grant CA70856 (JA Pietenpol), US Army Grant DAMD17-99-1-9422 (JA Pietenpol), and National Institutes of Health Grants ES00267 and CA68485 (Core services).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, Z., Tang, L. & Pietenpol, J. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20, 113–124 (2001). https://doi.org/10.1038/sj.onc.1204060

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204060

Keywords

This article is cited by

Search

Quick links